Compare Abeona Therapeutics Inc (ABEO) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Ryanair Holdings plc — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Ryanair Holdings plc trades at $65.59 (market cap $32.49B). The key difference: Ryanair Holdings plc is far larger — about 87× Abeona Therapeutics Inc's market cap, and Ryanair Holdings plc pays a 1.49% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | RYAAY | |
|---|---|---|
Market Cap | $373.32M | $32.49B |
Sector | Health | Industrials |
52-Week High | $7.23 | $73.82 |
52-Week Low | $4.17 | $53.24 |
Enterprise Value | $228.22M | $30.15B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Ryanair Holdings (RYAAY) trades at $66.35, up 1.31% with bullish technical signals from moving averages. The company demonstrates strong fundamentals with a P/E of 14.42, net income margin of 13.98%, and consistent earnings beats. Recent traffic growth of 7% in June 2026 and improved family seating policy reflect operational strength. Cash flow from operations remains robust at $3.42B despite negative net cash flow of -$12M in 2025.
RYAAY presents a compelling investment case with analyst consensus favoring Buy (62.5%) and bullish technical indicators. The airline's debt-free balance sheet, 80% fuel hedge for 2027, and cost leadership provide competitive advantages. Key risks include rising operating costs, macroeconomic uncertainty, and potential regulatory pressures. The stock's current valuation appears reasonable given strong profitability metrics and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
